PharmaEssentia Corporation
6446
Classifica tra le azioni
#1441
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Prezzo delle azioni
$36.89
Capitalizzazione di mercato
$15.25B
Variazione (1 giorno)
-1.28%
Variazione (1 anno)
144.12%
Paese
TW
Scambia PharmaEssentia Corporation (6446)
Categoria
Healthcare
Rapporto P/S per PharmaEssentia Corporation (6446)
Rapporto P/S al October 2026 TTM: 23.96
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di PharmaEssentia Corporation, il rapporto P/S attuale (TTM) è 23.96. Alla fine del 2023, era pari a 22.06.
Storico del rapporto P/S per PharmaEssentia Corporation da 2010 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 23.96 | 16.52% |
| 2024 | 20.56 | -6.80% |
| 2023 | 22.06 | -53.07% |
| 2022 | 47.01 | -58.98% |
| 2021 | 114.59 | 181.19% |
| 2020 | 40.75 | -46.81% |
| 2019 | 76.61 | -94.54% |
| 2018 | 1.40K | -81.75% |
| 2017 | 7.68K | 27.57% |
| 2016 | 6.02K | 95.48% |
| 2015 | 3.08K | 61.64% |
| 2014 | 1.91K | 276.50% |
| 2013 | 506.34 | -45.75% |
| 2012 | 933.30 | -41.98% |
| 2011 | 1.61K | 237.00% |
| 2010 | 477.29 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -70.54% |
IN
|
